Julie Chang, MD, discusses the reasoning behind the development of a minimal residual disease-adapted study in patients with previously untreated mantle cell lymphoma.
Julie Chang, MD
Advertisement
Julie Chang, MD, is an associate professor of medicine at the University of Wisconsin School of Medicine and Public Health in Madison, WI.
Articles by Julie Chang, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
